IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

Phase 1IDE892Positive

AI Analysis

Summary

IDEAYA Biosciences announced IDE892, a selective PRMT5 inhibitor with potential best-in-class profile, and initiated Part 2 monotherapy expansion in its Phase 1/2 study in MTAP-deleted pancreatic and lung cancers.

Clinical Trial Data

Phase

1/2

Outcome Details

Initiated Part 2 monotherapy expansion in Phase 1/2 study

Importance:5/10

Sentiment:

0.60

PRMT5 inhibitoroncologypancreatic cancerlung cancerMTAP-deletedclinical trialmonotherapy

Related Companies

$IDYA

Read the original article

Published by PR Newswire Biotech on July 27, 2026 10:00 AM

Read Original